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 New lasers and light sources – old and 
new risks? 
 Summary 
 Recent developments (new wavelengths, treatment concepts, and combinations) in 
the field of lasers, intense pulsed light (IPL), LED, as well as new energy and light sour-
ces have opened up new therapeutic options that extend beyond mere aesthetic in-
dications. Thus, while fractional lasers used to be employed to merely treat wrinkles, 
the same devices – in the context of laser-assisted drug delivery – have now become 
important tools in the treatment of scars, field cancerization, and epithelial tumors. 
The requirements posed to physicians, both with respect to establishing the indicati-
on and conducting treatment, have been growing along with the increase in techno-
logical complexity as well as the rising number of comorbidities and comedications in 
a patient population that continues to age. 
 At the same time, home-use devices have been introduced for a variety of indica-
tions. These devices are characterized by low power and special safety features aimed 
at preventing accidents, risks, and side effects. Despite the reduced efficacy of such 
self-treatment devices, there is an increased risk of misuse, given that the basic pre-
requisite for adequate treatment cannot be ensured, to wit, the exact diagnosis and 
therapeutic indication. Consequently, during hair removal or anti-wrinkle treatment, 
pigmented lesions and cutaneous neoplasms may be altered, thus giving rise to ex-
pected, unexpected and new side effects and complications. 
 In the aforementioned setting, it is important that all potential users of these new 
technologies be properly trained in a manner that ensures those treated a maximum 
of safety and efficacy in accordance with the guiding principle “ diagnosis certa – ullae 
therapiae fundamentum ”. 
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 Introduction 
 Recent developments (new wavelengths, treatment concepts, 
and combinations) in the fi eld of dermatological lasers, in-
tense pulsed light (IPL) devices, LEDs (light-emitting diodes), 
and new light sources have opened up additional indications 
and therapeutic options for dermatologists. Remarkably, des-
pite the growing number of comorbidities and comedications 
in an aging society, there is an increased demand for aesthetic 
procedures. As a consequence, taking a precise patient his-
tory and conducting a thorough diagnostic workup prior to 
treatment becomes a sine qua non. 
 A new aspect is the merging of aesthetic treatment and the-
rapeutic intention, for example, in the treatment of photoaged 
skin. Thus, while fractional lasers used to be employed to me-
rely treat wrinkles and dyspigmentation, the same devices – in 
the context of laser-assisted drug delivery – have now become 
important tools in the treatment of fi eld cancerization. Apart 
from the correct indication, safe and effective treatment requires 
comprehensive patient information with regard to benefi ts, ris-
ks, and limitations of the procedure to be performed, as well as 
adequate parameter selection and patient follow-up. Given that 
binding standards for laser therapy (in humans) do not exist  [ 1 ] , 
this challenge can only be met with thorough user training  [ 2–5 ] . 
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 The most common source of complications are “health 
care providers” (that is, non-medical personnel). Approxima-
tely 30 % of complications, such as burns, scars, dyspigmen-
tation, and infections, can be attributed to these individuals 
alone  [ 6–8 ] , whereas all other user groups are less commonly 
responsible for said adverse events. More than two-thirds of 
all complications are caused by incorrect parameter selection 
 [ 7 ] . By contrast, trained dermatologists with years of expe-
rience can achieve a complication rate as low as 0.24 %  [ 9 ] . 
 Against this backdrop, the recent introduction of ho-
me-use devices for epilation and the treatment of aging skin 
must be critically assessed. Based on published evidence, we 
will summarize classic, well-known, and thus avoidable risks 
and side effects. In addition, potential risks associated with 
the use of new therapeutic concepts, systems, lasers, as well 
as energy and light sources are highlighted. 
 General hazards associated with lasers, 
intense pulsed light devices, and new 
light sources 
 Long established in routine clinical practice, lasers, IPL and 
radio frequency devices generally represent safe technologies. 
Nevertheless, injuries to patients have been reported for all 
device classes (Medical Device Reports [MDR] in: Manufac-
turer and User Facility Device Experience [MAUDE] – FDA 
data on complications with lasers, light sources, and ener-
gy-based devices)  [ 6, 10 ] , in particular when operated by 
non-medical personnel  [ 6, 8 ] . Of the 1,257 adverse events 
documented between 1991 and 2013, injuries to the eyes, 
which are particularly damaging, were predominantly cau-
sed by IPL devices  [ 10 ] . 
 In order to answer the question whether IPL treatment 
is potentially more harmful to the skin than laser treatment, 
various aspects have to be considered. On the one hand, 
various device generations are currently being used, with 
fi rst-generation devices employing different technologies 
than subsequent systems (square pulse/free discharge). This 
affects the stability of the emitted pulse during the applica-
tion cycle and thus has direct effects on the expected side 
effect profi le  [ 11–13 ] . First-generation IPL devices emit light 
in the infrared spectrum, often resulting in collateral damage 
to the epidermis and a high incidence of adverse effects. In 
second-generation IPL devices, the unwanted infrared com-
ponent is fi ltered out by water, thus signifi cantly reducing the 
risk of adverse events  [ 14, 15 ] . This, however, does not apply 
to the off-label use of these devices. In this context, the use 
of IPL in the treatment of tattoos is particularly problematic 
and may even have legal implications. 
 Manufacture, handling, and maintenance of medical la-
sers as ‘medical devices’ are regulated by law. International 
standards apply with respect to their use, safety inspections 
( sicherheitstechnische Kontrollen, STK ), documentation, 
and maintenance. Pursuant to STK Article 6 of the German 
Medical Device Operator Ordinance ( Medizinprodukte-Be-
treiberverordnung [MPBetreibV] ), test reports have to be 
prepared on a regular basis at 6-, 12-, or 24- month inter-
vals, depending on manufacturer specifi cations. For each in-
dividual device, these checks include a visual inspection of 
the exterior of the device (protective ground wire, insulation, 
casing, connection cable, type label), a power-on check, po-
wer measurements including a reference value check, electri-
cal measurements (protective ground wire resistance [R PG], 
insulation resistance [R Ins], U ins leakage current [I L],  Δ I), 
and functional tests (U LN,  Δ I, I V, LF). 
 Medical lasers are also subject to international stan-
dards with respect to their emitted radiation (measured in SI 
units) (Système international d’unités, international system 
of units): measured deviations must not exceed ± 20 % (mea-
sured in SI units). 
 For IPL devices, there are no such standards that have to 
be adhered to  [ 16 ] . It is merely recommended that the data 
provided by the manufacturer be compared with own mea-
surements of the handpiece and documented in an inspection 
book (FA ET 3 2009). However, such initial or even recurrent 
measurements are not mandatory. This is also true for mea-
surements of the applied energy. It is, however, recommended 
to measure fi ve key parameters in order to minimize risks 
associated with over- or undertreatment. Based on these pa-
rameters, service technicians are able to check performance 
and eliminate device malfunction  [ 17 ] . 
 The relevance of these checks is refl ected by the fact that 
operator errors due to incorrect parameter selection and im-
proper device maintenance are responsible for the majority 
of adverse events and complications. Apart from radio fre-
quency devices, diode lasers, IPL devices, and – since 2003 
– BBL (broadband light) devices have been the systems most 
commonly associated with side effects. The latter have most 
frequently been used for hair removal  [ 10 ] . 
 Ultimately, the technology behind IPL devices is one rea-
son for their exceptionally high rate of side effects, given that 
their wavelength spectrum is not as precisely defi ned as is 
the case with lasers  [ 18 ] . The required wavelengths are achie-
ved by upstream cutoff fi lters and integrated water fi lters. 
Depending on the device generation, however, the patient’s 
skin may also be exposed to and damaged by infrared and 
blue light as well as UV radiation  [ 14, 15, 17 ] . Consequent-
ly, a wide range of side effects may be expected, including 
erythema, skin aging, potential induction of neoplasms  [ 19 ] , 
phototoxic and photoallergic reactions, and many more (FA 
ET 3 2009). 
 Legal certainty had been expected from the Protection 
against Non-ionizing Radiation Act ( Gesetz zum Schutz vor 
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nichtionisierender Strahlung [NiSG] ) passed in 2009. Article 
3 of the NiSG regulates the protection of individuals during 
the use of cosmetic or other devices outside the medical fi eld, 
including lasers or IPL devices. Article 5 of the NiSG specifi es 
the scope of the regulations. Among other things, it is meant 
to regulate qualifi cation certifi cates, threshold values, and 
technical inspections. Though highly relevant with respect 
to the legally compliant use of such devices in the cosmetic 
sector as well as to the health protection of users thereof, this 
regulation is still not available ( German Parliament, docket 
number 18/2163 ). 
 Epilation 
 Epilation enjoys continued popularity. With the exception of 
scalp hair, the last remnants of body hair have – for millen-
nia – been removed with increasingly sophisticated methods: 
plugging, shaving with sharpened stones, shells, and blades, 
epilation with resins, wax, as well as chemical procedures. 
The limited effi cacy of conventional epilation techniques 
has boosted the demand for procedures with permanent or 
at least long-lasting results. Moreover, continued medical 
progress has brought about new (iatrogenic) indications for 
epilation, for example, due to adverse drug reactions or as a 
result of surgical interventions such as defect coverage with 
hair-bearing skin in the context of skin cancer treatment. 
 The discovery of selective photothermolysis and the appli-
cation of this concept for effective and lasting photoepilation 
using various wavelengths have provided physicians with nu-
merous highly effective laser and IPL systems. The wide ran-
ge of devices and applications requires profound knowledge 
in order to provide patients with safe and effective treatment 
strategies as well as to identify potential drug interactions 
(Table  1 ) and reliably master special cases and complications 
(Table  2 )  [ 20 ] . This especially holds true in light of the fact that 
this particular procedure is the one most commonly associated 
with complications  [ 6, 21–23 ] . Given the numerous known – 
and sometimes common – side effects, it is recommended to 
use checklists  [ 24 ] (Table  3 ) In order to avoid complications 
and, in particular, interactions with comedications (Table  1 ). 
Moreover, physicians should be cognizant of and observe spe-
cifi c risk-increasing cofactors  [ 20 ] . Although photosensitizing 
drugs are usually activated by UVA, it is always recommended 
to fi rst treat only a small area and see how the skin reacts. 
 Commonly used devices include the alexandrite laser with 
a wavelength of 755 nm and the diode laser with a wavelength 
of 810 nm. The mode of action of both wavelengths has thus 
been comprehensively studied. Until now, these devices have 
 Table 1  Photosensitizing drugs (from  [ 20 ] ). 
 Diuretics Hydrochlorothiazide, furosemide, bendroflumethiazide, amiloride, etacrynic acid, 
triamterene, spironolactone, xipamide* 2 
 Nonsteroidal antiinflammatory 
drugs 
Naproxen, ketoprofen, tiaprofenic acid, piroxicam, diclofenac, phenylbutazone, 
mefenamic acid, indomethacin, ibuprofen 
 Antimicrobial agents Sulfamethoxazole/trimethoprim, sulfasalazine, ciprofloxacin, enoxacin, lomefloxacin, 
ofloxacin, norfloxacin, oxytetracycline, tetracycline, doxycycline, minocycline, 
isoniazid, gentamycin, griseofulvin, nitrofurantoin 
 Antimalarial agents Chloroquine, quinine, pyrimethamine, mefloquine, hydroxychloroquine 
 Antipsychotic drugs Chlorpromazine, thioridazine, promethazine, chlorprothixene, perazine, fluphenazine, 
promazine, haloperidol 
 Antidepressants Amitriptyline, trimipramine, nortriptyline, desipramine, imipramine, doxepin, 
clomipramine* 2 
 Cardiovascular agents Amiodarone, nifedipine, quinidine, captopril, enalapril, fosinopril, ramipril, 
disopyramide, hydralazine, simvastatin 
 Antiepileptic drugs Carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate* 2 , valproic acid* 2 
 Antihistamines Cyproheptadine, diphenhydramine, loratadine 
 Cytotoxic agents Fluorouracil, vinblastine, dacarbazine, procarbazine, methotrexate, azathioprine 
 Hormones Corticosteroids, estrogens, progesterone, spironolactone 
 Systemic dermatological agents Isotretinoin, alitretinoin, tretinoin, methoxsalen (8-methoxypsoralen) 
 Others Gold salts, hematoporphyrin 
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been characterized by their technically limited spot size, re-
sulting either in time-consuming treatment sessions or in the 
use of scanners. Drawbacks of scanners include the technical 
necessity for overlapping passes and their susceptibility to mal-
function. The need for fast laser systems that can be used to 
treat large areas, in particular for hair removal, has been met 
with linear-scanning and continuous-wave diode lasers  [ 20 ] . 
The latter are now also available with wavelengths of 755 nm 
and 1,064 nm  [ 27 ] . Based on initial studies, classic alexandrite 
lasers and the aforementioned novel diode lasers are almost 
identical with regard to effi cacy and side effects  [ 25 ] . 
 Treatment duration is markedly reduced and the ener-
gy to be applied is lower; in theory, the hair bulbs are thus 
exposed to heat both for a longer period of time and more 
evenly. For this purpose, a diode laser block is arranged in 
such a way that yields a “spot” with an approximate size of 
1 mm x 10–20 mm. Using mobile mirrors, the spot can then 
be continuously passed across the skin within a diameter of 
up to 5 cm. Alternatively, a diode laser block sized > 1 cm 2 can 
be constructed, and continuously passed over large areas (su-
per hair removal [SHR] concept). Both options result in very 
large treatment areas. In the case of linear-scanning systems, 
the movement speed can be adjusted by software. While this 
leads to exposure times (corresponding to conventional pulse 
durations) that are comparable to conventional systems, they 
are, however, less painful due to their successive application 
 [ 20 ] . With respect to SHR, the operator plays a pivotal role 
as it behooves him to precisely defi ne the size of the area to 
be treated and to ensure the homogeneous distribution of the 
total amount of energy applied. Too little energy results in 
therapeutic failure, and too much energy increases the risk of 
side effects and complications  [ 27 ] . 
 One problem of employing selective photothermolysis 
in the treatment of large areas is the accidental irradiati-
on of pigmented lesions with the potential risk of inducing 
 Table 3  Specific risk-increasing cofactors in laser therapy. 
 Specific, risk-increasing cofactors 
 –  Current photosensitizing medication (compare Table  1 ) 
 –  Topical/systemic agents: for example, retinoids, 
immunosuppressants 
 –  Negative effectors of wound healing: anticoagulant 
medication, diabetes 
 –  Diseases associated with Koebnerization: psoriasis, 
lichen planus, Darier’s disease, vitiligo 
 –  Autoimmune disorders, diseases with increased pho-
tosensitivity (PCT) 
 –  Allergic reactions to drugs (for example, local anes-
thetics, ointment bases, antiviral drugs, antibiotics) 
 –  Recent UV exposure, even mild suntan 
 –  History of or active herpes infection 
 –  Recurrent infections in the treatment area 
 –  History of or current keloids/hypertrophic scars 
 –  Dyspigmentation, lentigines, tattoos in the treatment 
area 
 Table 2  Published side effects associated with laser epilation, 
shortened from  [ 20 ] . 
 Item 
 Immediate reactions 
 –  Burns and curling of external hair components, 
burned smell, plume 
 –  Diffuse erythema 
 –  Perifollicular erythema 
 –  Perifollicular edema/wheals 
 –  Treatment-associated pain 
 –  Cold urticaria 
 Delayed reactions 
 –  (Diffuse) erythema 
 –  Blistering/erosions 
 –  Purpura 
 –  Crusting 
 –  Hyperpigmentation 
 –  Hypopigmentation 
 –  Folliculitis, acneiform reactions, exacerbation of acne, 
infections 
 –  Scars 
 –  Koebnerization, vitiligo, psoriasis, Lichen planus 
 –  Changes in nevi after photoepilation 
 –  Thrombophlebitis 
 –  No effect, partial or complete hair regrowth 
 –  Angular cheilitis 
 –  Focal depigmentation of the lips 
 –  Allergic reaction to cryospray 
 –  Hyperhidrosis, bromhidrosis after axillary epilation 
 –  Leukotrichia 
 –  Paradoxical hair growth in the treated area or adjacent 
to it 
 –  Pili bigemini 
 –  Dry skin 
 –  Reactivation of herpes simplex 
 –  Bacterial infection 
 –  Livedo reticularis 
 –  Urticarial vasculitis 
 –  Pruritus 
 –  Excoriation 
 –  Terminalization of hairs 
 –  Induction of rosacea 
 –  Textural changes 
 –  Brightening of pigmented lesions 
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malignancies. The guidelines of the European Society for 
Lasers and Energy-Based Devices (ESLD; the European Gui-
delines for Care) recommend that the lesions be covered  [ 27 ] . 
However, side effects cannot be ruled out, given the high 
energy used in linear-scanning systems and the successive, 
repetitive heating associated with SHR systems (unpublis-
hed data). The use of various cover materials has previously 
been reported in connection with conventional UV and laser 
light sources. Simple application of thick layers of zinc paste 
has been shown to be effective in the new, linear-scanning 
epilation system with spacer  [ 27 ] ; this has also been confi r-
med histologically  [ 26 ] . As with all other cover concepts, this 
method cannot be used when employing epilation lasers that 
require skin contact, irrespective of whether they are scanned 
or used as SHR device. Finally, it should be emphasized that 
nonpigmented, yet palpable skin lesions, too, may in reality 
represent malignant melanocytic tumors  [ 27 ] . This situation 
once more highlights the necessity for thorough assessment 
of the skin in the entire treatment area. 
 Another new development has been the introduction of 
home-use laser epilation systems  [ 28, 29 ] . Given the greatly 
reduced fl uence for safety reasons, one may assume that hair 
removal is rather transient and less effective. Here, a new 
and grave risk is the chronic application of laser radiation to 
pigmented skin lesions  [ 27 ] that should not be treated with 
lasers  [ 30 ] . From a dermatological perspective, this develop-
ment should therefore give rise to concern  [ 27 ] . So far, pub-
lished side effects correspond to those already known  [ 31 ] . 
 Photoepilation as such is prone to complications and 
even more so when IPL devices are used  [ 6 ] . Avoiding UV 
exposure prior to and at least 24 hours after IPL treatment 
is of particular importance. Even the single application of 
> 3 SEDs (standard erythema dose) has been shown to cause 
numerous adverse effects such as erythema (87 %), purpura 
(27 %), blisters (20 %), edema (13 %), crusting (13 %), hy-
perpigmentation (60 %), and hypopigmentation (20 %)  [ 32 ] . 
Due to phototoxic reactions and bulk heating, tattoos in the 
epilation area are a recurrent source of adverse events. “Tre-
atment” of pigments using IPL devices almost always results 
in complications. It is therefore important to raise all relevant 
issues in the informed consent discussion (Table  4 ) and to use 
checklists prior to treatment initiation (Table  5 ). 
 In addition, the technical report IEC TR60825-9 illus-
trates the ocular risks associated with incoherent light sour-
ces. Nevertheless, when used correctly, IPL systems may be 
employed as reliably as diode lasers if the operator is adequa-
tely trained  [ 33 ] . 
 Fractional photothermolysis 
 In light of an increased cumulative UV exposure in com-
bination with a longer life expectancy, dermatologists are 
increasingly confronted with their patients’ request to treat 
their chronically photoaged skin, that is wrinkles, dyspig-
mentation, scars, and obvious as well as incipient neoplastic 
changes as a consequence of sun damage  [ 34 ] . In this context, 
laser procedures are of particular importance as they have 
become less and less invasive due to technological advances. 
 In the past, good clinical effects were primarily achieved 
with CO 2 and Er:YAG lasers, which allow for the two-di-
mensional ablation of large areas of the skin. However, the 
excellent therapeutic effects of the CO 2 laser have to be weig-
hed against the pronounced side effects and the long time 
required for healing (“down time”; period during which 
the patient cannot participate in public life; also, time until 
re-epithelialization)  [ 35 ] . 
 Recent developments in the fi eld of laser systems have 
allowed for continued conceptual advances  [ 36 ] , resulting in 
the development of fractional photothermolysis  [ 37 ] . Here, 
the single laser beam is divided into numerous microscopic 
laser beams, comparable to water fl owing from a shower 
 Table 4  Important items in the informed consent discussion 
prior to laser epilation. 
 –  Overall, complications are rare in case of adequate, 
skin type-adapted parameter selection. 
 –  Side effects are more common when treating dark-
skinned individuals (Fitzpatrick IV–VI)  [ 86 ] . 
 –  Depending on the wavelength employed, the most 
common side effects include erythema, burns, 
blistering/crusting, hypopigmentation, hyperpig-
mentation, and scarring  [ 87 ] . 
 Table 5  Checklist for laser epilation. 
Short checklist for the assessment of initial clinical 
findings, modified after  [ 88 ] . 
 1  Classification of the abnormal hair growth (hirsutism, 
hypertrichosis, others) 
 2  Clinical/diagnostic evaluation as to whether there is a 
potential underlying pathomechanism that may also 
require treatment: endocrine, drug-induced, associa-
ted with a neoplasm or a syndrome, constitutional 
 3  Are there any other known disorders or allergies? 
 4  Which drugs are taken or topically applied? 
 5  Sun tolerance? 
 6  Which steps have been taken to treat the abnormal 
hair growth? Have there been any problems? 
 7  Determination of contraindications/risk-increasing 
cofactors 
Review Article New lasers and light sources – old and new risks?
492 © 2017 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd. | JDDG | 1610-0379/2017/1505
head  [ 38 ] . Through nonspecifi c coagulation (without abla-
tion), these lasers were initially used to create column-like 
defects in the skin, which resulted in clinical improvement of 
treated lesions (scars, sun-damaged skin) during the wound 
healing process  [ 34 ] . 
 Following several clinical studies  [ 37, 39, 40 ] , the prin-
ciple of fractionated heat delivery into the skin (non-ablative 
fractional laser therapy; NAFXL) was approved by the US 
Food and Drug Administration (FDA) for the treatment of 
wrinkles, dyspigmentation, and the coagulation of connecti-
ve tissue. The latest development combines the basic princi-
ples of fractional photothermolysis and classic ablative laser 
procedures by introducing microscopic channels into the skin 
[ablative fractional laser therapy; AFXL)  [ 41 ] . The impact of 
the selected laser parameters on the ablation characteristics 
has been systematically evaluated in pigskin  [ 42 ] . 
 It has also been shown that these systems are effective 
in neoplastic skin  [ 43 ] and that suitable suction devices en-
sure the safety of patients and physicians even when large 
amounts of tissue are ablated  [ 44 ] . In clinical studies  [ 45, 46 ] , 
ablative fractional laser therapy, which is usually conducted 
using Er:YAG, Er:YSGG, and CO 2 lasers, showed compara-
ble and promising results in the treatment of sun-damaged 
and thus potentially neoplastic skin as well as scars  [ 47, 48 ] . 
Based on these fi ndings, an in vitro explant model was esta-
blished to study the individual and combined effects of va-
rious laser systems on the skin. HSP70 (heat shock protein 
70) is a crucial trigger point for scar-free wound healing as 
well as the treatment of neoplastic skin using photodynamic 
therapy and ablative fractional lasers  [ 49–56 ] . Subsequently, 
the spatiotemporal healing process was analyzed in vivo, and 
threshold values (spot size 250  μ m, coverage < 50 %, fl uence 
< 100 mJ for the Quantel Exelo 2 system) for safe and effective 
treatment were determined  [ 57, 58 ] . These were then confi r-
med by optical coherence tomography and refl ectance con-
focal microscopy  [ 59 ] . 
 To date, numerous ablative fractional CO 2 lasers are 
FDA-approved for ablation, coagulation and remodeling of 
soft tissue, treatment of wrinkles, dyspigmentation, vessel-re-
lated discolorations, and especially for scars, all changes re-
lated to extrinsic skin aging  [ 60 ] . Today, fractional lasers are 
considered the standard in dermatology  [ 41 ] . Nevertheless, 
further developments of fractional laser systems are required 
in order to safely establish potential areas of application in 
routine clinical practice  [ 61 ] . 
 Thus, the spectrum of indications for these lasers is con-
tinuously being expanded. These systems are already used 
for neoplasms, fi brosing skin diseases, infl ammatory skin di-
seases, and for the removal of foreign bodies. Their potential 
lies in the temporary opening of the epidermal barrier (TOR) 
 [ 61 ] . While the TOR (German for “gate”) to the skin literal-
ly has the potential to pave the way to new and intensifi ed 
therapies, it has also brought to light numerous new risks 
 [ 62 ] . Given that the concept of these new techniques, which 
can be summarized as laser-assisted drug delivery (LADD), 
is to make the skin distinctly more penetrable than usual, it is 
imperative that the indication be established by a board-cer-
tifi ed specialist. The enhanced penetration of drugs is associ-
ated with an increased risk of side effects and complications 
due to systemic absorption and effects, inoculation of patho-
gens, sensitizations, and anaphylactic reactions. 
 Currently, LADD is employed for the sustained treat-
ment of fi eld cancerization. It has been shown that laser-as-
sisted photodynamic therapy (PDT) is superior to conventio-
nal PDT in treating actinic keratosis and fi eld cancerization, 
especially in immunosuppressed patients  [ 63–66 ] . It does 
even have preventive effects  [ 67 ] . In superfi cial and nodu-
lar basal cell carcinoma, the effi cacy of conventional PDT 
can be enhanced as well  [ 68, 69 ] . Recent studies confi rm 
the increased effi cacy of topical antineoplastic agents such 
as ingenol mebutate  [ 70 ] and methotrexate (MTX)  [ 71, 72 ] , 
as well as other topical drugs such as 5-fl uorouracil (5-FU) 
 [ 62 ] . Essential steps in the improvement of therapeutic con-
cepts are geared towards increased reliability and effi cacy in 
the case of evident and incipient neoplasms in chronically 
photodamaged skin. Current examples include the sequenti-
al use of synergistic lasers to maximize the HSP70 response 
 [ 49 ] , the application of pressure to induce deep drug delivery 
following fractional ablation  [ 73 ] and the use of nanotrans-
porters  [ 61 ] . 
 Recent studies on the utilization of alternative light sour-
ces for PDT demonstrate the importance of medical supervi-
sion when using these new, highly effective therapies. PDT 
is always painful when used according to standard procedu-
res. While preliminary studies show very positive results for 
daylight-mediated PDT (shortened incubation time)  [ 74–76 ] , 
numerous cofactors can signifi cantly limit its effi cacy  [ 77 ] . 
Adequate medical assistance is therefore a sine qua non in 
any kind of LADD. 
 Vessels 
 Historically, the treatment of unwanted vessels is one of the 
most common interventions. Here, too, a thorough diagno-
stic workup prior to the intervention is crucial, given that 
especially malignant vascular neoplasms may show slow 
clinical progression. Apart from IPL devices, argon lasers 
(488/514 nm), alexandrite lasers (755 nm), Nd:YAG lasers 
(1,064 nm), dye lasers (585/595/600 nm), and potassium ti-
tanyl phosphate (KTP) lasers (532 nm) have been extensively 
used for the treatment of superfi cial teleangiectases, heman-
giomas, and other vascular lesions  [ 27 ] . 
 The argon laser emits a blue-green light of the wavelengths 
488 nm and 514 nm with low epidermal penetration. Its use 
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is commonly associated with adverse effects such as persis-
tent postinterventional hyperpigmentation and scar formati-
on  [ 27 ] . Lasers that emit light of 532 nm are similarly effecti-
ve and characterized by similar side effects. Here, the use of 
KTP or lithium borate (LBO) crystals results in doubling of 
the frequency (1,064 nm). 
 The long-pulsed alexandrite laser (755 nm, up to 20 ms) 
and diode lasers (800 nm, 810 nm, 930 nm, 10–250 ms) 
have been shown to be less effective in the treatment of very 
thin vessels  [ 27 ] . Short-pulsed alexandrite lasers are charac-
terized by very high effi cacy and a very narrow therapeutic 
range. A rather high risk of side effects must be expected 
when using long-pulsed Nd:YAG lasers (1,064 nm, pulse up 
to 20–100 ms), although they are exceptionally effective if 
employed correctly  [ 78 ] . Here, the competent management of 
potential side effects (hyperpigmentation, textural damage, 
hemorrhage) is of particular importance. 
 Recently, there has been an increasing number of pub-
lications describing the use of well-established wavelengths 
under certain conditions or in combination in order to im-
prove success rates. Treatment-refractory, especially dark 
and hypertrophic nevi fl ammei pose a particular challenge. 
Tuberous components can be treated quite well with the 
long-pulsed Nd:YAG laser or the short-pulsed alexandrite 
laser with larger spot sizes, while accepting a higher risk of 
scar formation, whereas plane components are diffi cult to 
treat with these lasers  [ 27 ] . Recent developments have shown 
good results in plane lesions using a combination with radio 
frequency-induced heating. 
 Alternatively, IPL devices can be used, in particular for 
extensive and small-caliber lesions. Here, too, special care 
must be taken when treating tanned individuals. Following 
treatment, UV exposure should be avoided for at least 24 
hours  [ 32 ] . 
 Pigment removal 
 A signifi cant innovation for the removal of unwanted skin 
pigmentations are systems that emit light in the picosecond 
(ps) range. However, it has been shown that these systems are 
no more effective in the treatment of tattoos than their na-
nosecond counterparts  [ 79, 80 ] . In addition, there have been 
reports of an interaction with the epidermis (laser-induced 
optical breakdown; LIOB), which presents as light-induced 
cutaneous perforation that is smaller than the spot size of the 
laser (EP2366355 A1). A conclusive assessment of the effects 
of these interactions on healthy, artifi cially changed, or di-
seased skin is not yet possible. 
 Fractional lasers have also been used to remove unwan-
ted pigment. Evidence of limited therapeutic success in me-
lasma was provided by the detection of melanin in the eli-
mination products occurring during postfractional wound 
healing  [ 62, 81 ] . These fi ndings are corroborated by reports 
that the pigment stored in melanophages is released follo-
wing their rupture and dispersed in the tissue. There is evi-
dence that fractional ablative interventions are well suited to 
treat dyspigmentation even in scars. However, it is important 
to keep in mind that fractional lasers should not be used in 
the treatment of melanocytic lesions, either  [ 27 ] . Still doing 
so requires a clear indication established by a board-certifi ed 
specialist. 
 Given their large wavelength spectrum, IPL systems 
have also been used to treat unwanted hyperpigmentation. 
Ultimately, the success rates are as low as for conventional 
Q-switched lasers that emit in the nanosecond (ns) range and 
are generally used for the removal of tattoos and pigmented 
lesions. Prior to any intervention, it is imperative to have a 
specialist determine whether the lesion to be treated is truly 
benign. 
 In accordance with the concept of selective photother-
molysis, only systems with very short pulse durations may be 
used for tattoo removal in order to minimize any collateral 
damage. A common problem is the competing target chromo-
phore melanin  [ 32 ] , which renders the procedure exceedingly 
prone to complications. In addition, the removal of dyes from 
the human skin is associated with risks such as allergic reac-
tions (especially for red dyes), color changes, formation of to-
xic degradation products, scarring, and incomplete removal 
even after many sessions  [ 82–85 ] . 
 Adverse effects are much more severe when IPL systems 
are used for tattoo removal. In this case, phototoxic reac-
tions, dyspigmentation, scars, and keloids have to be expec-
ted. Periocular use bears the risk of additional complications. 
 Summary and outlook 
 Recent developments (new wavelengths, concepts, and com-
binations) in the fi eld of lasers, intense pulsed light devices, 
LED, as well as new energy and light sources have provided 
dermatologists with new areas of application, therapeutic op-
tions, and aesthetic indications. 
 These developments have brought about a merging of 
aesthetic indication and therapeutic intention. For example, 
while fractional lasers used to be employed solely for aes-
thetic indications, today these systems – in the context of 
LADD – have become important tools in the treatment of 
fi eld cancerization. Along with greater effi cacy, improved 
techniques, and implemented safety requirements, physicians 
are confronted with increasing demands, also due to potenti-
al interactions with a growing number of comorbidities and 
comedications in a patient population that continues to age. 
 In order to avoid treatment errors, it is therefore essential 
that the indication be established by a physician, in particu-
lar when procedures are employed that include coagulation 
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(vessel-occlusion), ablation, fractional treatment, pigment 
removal, and epilation. Access to any device that might be 
used incorrectly should be denied to laypersons as well as 
medical personnel without specifi c training and thus without 
diagnostic competence. 
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